European Leukemia Trial Registry
Trial: AMLSG 16-10

More Details
Title Protocol in Acute Myeloid Leukemia With FLT3-ITD
Scientific Title Phase-II study evaluating midostaurin in induction, consolidation and maintenance therapy also after allogeneic blood stem cell transplantation in patients with newly diagnosed acute myeloid leukemia exhibiting a FLT3 internal tandem duplication
Short Title AMLSG 16-10
Trialgroup AMLSG Ulm
Type of Trial multicentric, single-group, prospective, open-label
Disease Acute myeloid leukemia(AML) AML all subtypes without FAB M3
Age <= 70 years
Status No longer recruiting
Start of Recruitment 03.05.2012
Leader Döhner, Prof. Dr. med., Hartmut
Contactperson

Study coordinator
Paschka, Dr., Peter
Tel: +49 (0)731 500 45757
Fax: +49 (0)731 500 45905
Email: Peter.paschka@uniklinik-ulm.de

General Contact Person
Münnich, Anja
Tel: +49 (0)731 500 45912
Fax: +49 (0)731 500 45905
Email: anja.muennich@uniklinik-ulm.de

Centre of Trial Universitätsklinikum Ulm
Shortprotocol Shortprotocol
Diagnostics

Cytogenetics
Labor für Zytogenetische und Molekulargenetische Diagnostik, Klinik für Innere Med. III, Universitätsklinikum Ulm

Remark Amendment der Studie
created 07.05.2012 Luise Kloos
changed 09.04.2018 Martina Wolkenfeld
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org